Opaleye Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Opaleye Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-955,000	Closed	-$2.07M	–	52
2021 Q3	$2.07M	Sell	955,000 -1,045,000	-52%	-$2.27M	0.39%	39
2021 Q2	$5.26M	Hold	2,000,000	–	–	0.87%	30
2021 Q1	$5.22M	Hold	2,000,000	–	–	0.77%	39
2020 Q4	$5.56M	Sell	2,000,000 -39,100	-2%	-$114K	0.73%	36
2020 Q3	$9.42M	Buy	+2,039,100	New	+$6.73M	1.84%	24
2019 Q1	–	Sell	-72,500	Closed	-$577K	–	63
2018 Q4	$577K	Buy	+72,500	New	+$1.05M	0.22%	43

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Opaleye Management's SIOX Position: Q4 2021 in Review

Opaleye Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 955,000 shares — an estimated $2.07M sold.

Opaleye Management first reported a position in SIOX in Q4 2018 and held it in 6 quarters. The position peaked at $9.42M in Q3 2020. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

Opaleye Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Opaleye Management sold 955,000 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $2.07M.
Opaleye Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2018 and held it in 6 quarters.
Opaleye Management's Sio Gene Therapies Inc. Common Stock position peaked at $9.42M in Q3 2020.
48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.